Error loading player: No playable sources found
Continuous Manufacturing for Emergency Preparedness and Rapid Response: Accelerating Widespread Adoption
Date
June 4, 2020
Continuous Manufacturing for Emergency Preparedness and Rapid Response: Accelerating Widespread Adoption|The onset of the COVID 19 pandemic has illustrated the importance of the FDA's desired state of a "maximally efficient, agile, flexible pharmaceutical manufacturing sector". Continuous manufacturing has the potential to rapidly respond to changes in demand due to local or global changes. Speakers in this session will discuss how government agencies, pharmacopeial organizations, and industry are working to advance continuous manufacturing and the potential of this technology to respond to the current situation and future challenges. This session will close with an extended panel discussion.
Leader/Speaker
Christine M. Moore, PhD
Executive Director, Quality Systems & Compliance, Organon LLC
Speakers
Stelios C. Tsinontides, Ph.D., FAIChE
Director, Office of Pharmaceutical Manufacturing Assessment (OPMA), OPQ, CDER, FDA
Atul Dubey, PhD
Director, Pharmaceutical Continuous Manufacturing, USP Reference Standards Labs
B. Frank Gupton, PhD
Floyd D. Gotttwald Professor & Chair, Chemical & Life Science Engineering, Virginia Commonwealth University
Anne Fischer, PhD
Programs Manager, Defense Science Office, Defense Advanced Research Projects Agency (DARPA)
Paul Collins, PhD
Senior Director, Small Molecule Design and Development, Eli Lilly and Company
Tracks
Related Products
Workshop: ICH Q9(R1) and Quality Risk Management
This workshop wasn't recorded, and on-demand content only includes the handouts…
Quality Management Maturity in Action
ISPE APQ Case Study and FDA QMM Program Learnings…
Drug Shortages: Progress in a Challenging Year
As we enter a transitional period within the pandemic, some uncertainties remain. The need to continually improve supply chain resiliency remains certain, as demonstrated by the challenges with Single Use Systems…
